Daniela C.
- Country
- Italy
- Department
- 138023: Ematologia
Research Overview
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
- Phase 3 Randomized Double‑Blind Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo + Ruxolitinib in JAK‑Inhibitor‑Naive Adults with Myelofibrosis
Data & Insights
Has run more than one trial at 236 of 406 partner sites.
Specializations
Myeloid Disorders
The investigator specializes in treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with particular focus on both higher-risk and lower-risk variants. Their research encompasses innovative therapeutic approaches for newly diagnosed cases and treatment-resistant conditions.
- RARA-positive MDS treatment strategies
- Novel combinations for refractory AML
- Anemia management in lower-risk MDS
Lymphoid Malignancies
The investigator focuses on advanced treatments for acute lymphoblastic leukemia (ALL), with specific expertise in both Philadelphia chromosome-positive and negative variants. Their work involves targeted therapies and immunotherapeutic approaches.
- Ph-like ALL treatment protocols
- Combination therapies with tyrosine kinase inhibitors
- Monoclonal antibody treatments
Myeloproliferative Disorders
The investigator conducts research in myelofibrosis and essential thrombocythemia, focusing on novel therapeutic approaches for patients with specific disease characteristics or treatment resistance.
- JAK inhibitor-naïve myelofibrosis treatment
- Essential thrombocythemia management
- Nuclear export inhibition strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.